Autolus Therapeutics (NASDAQ:AUTL) Sets New 1-Year High – Still a Buy?

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) reached a new 52-week high on Wednesday . The company traded as high as $2.46 and last traded at $2.4150, with a volume of 444143 shares traded. The stock had previously closed at $2.29.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AUTL. Wall Street Zen raised shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, August 3rd. Finally, Weiss Ratings raised Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Autolus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Autolus Therapeutics Price Performance

The company has a current ratio of 4.89, a quick ratio of 4.40 and a debt-to-equity ratio of 1.04. The stock has a market cap of $641.98 million, a price-to-earnings ratio of -2.28 and a beta of 2.07. The stock has a 50-day moving average price of $1.67 and a two-hundred day moving average price of $1.58.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.06. The business had revenue of $45.69 million during the quarter, compared to analysts’ expectations of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. As a group, equities research analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.8 EPS for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of large investors have recently bought and sold shares of AUTL. GAMMA Investing LLC lifted its holdings in Autolus Therapeutics by 115.6% in the 2nd quarter. GAMMA Investing LLC now owns 15,499 shares of the company’s stock valued at $25,000 after purchasing an additional 8,309 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of Autolus Therapeutics by 2.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock valued at $722,000 after buying an additional 11,197 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Autolus Therapeutics by 41.6% in the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after buying an additional 11,289 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Autolus Therapeutics by 53.3% in the first quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after buying an additional 11,381 shares in the last quarter. Finally, Marex Group plc purchased a new position in shares of Autolus Therapeutics in the second quarter worth about $28,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.